Vericel(VCEL)
CAMBRIDGE, MABiotechnology
Focus: Vericel is a public biotechnology company specializing in cellular therapy for orthopedic, cardiovascular, and regenerative medicine indications. The company generated $198M in revenue in FY2025 with a diversified pipeline of autologous cell therapies.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1-50
Total Funding
$6.5M
Open Jobs
20
Should You Work at Vericel?
AI assessmentVericel offers a rare sweet spot for mid-career professionals seeking exposure to cell therapy commercialization with public company stability, but requires comfort with modest margins and execution risk on Phase 2/3 clinical programs.
Why Work Here
- Public company with established $198M revenue base and positive momentum (+21% YoY growth FY2024-2025) provides stability and upside potential
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$198M
Key Products
Carticel
Stable
Peak
Phase 4 marketed product forming revenue base; represents established cell therapy franchise in orthopedics.
MACI
Help build intelligence for Vericel
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.